Method of controlling nephrotoxicity of anti-tumor plaintum compounds
US5002755A · kind A · utility
15Cited by
1References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 24, 1989 |
| Grant date | Mar 26, 1991 |
| Priority date | — |
| Expiry date | Apr 24, 2009 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K33/243
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Nephrotoxicity of anti-tumor platinum coordination compounds (e.g., cisplatin) is reduced by administering a dithiocarbamate chelator (e.g., diethyldithiocarbamate) at least 12 hours before as well as immediately after the administration of the anti-tumor compound.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.